Last
Update:
April 03, 2015
Documents identified with this icon are in Portable Document Format (PDF)
and require the
Adobe
Acrobat Reader
|
Journal Papers, Abstracts, and Commentaries
| |
Four days a week or less on appropriate
anti-HIV drug combinations provided long-term optimal
maintenance in 94 patients: the ICCARRE project.
Leibowitch J, Mathez D, de Truchis P, et al
FASEB J.
2015 Apr 1
Abstract
FULL-TEXT PDF ARTICLE
Outcomes of second-line combination antiretroviral therapy
for HIV-infected patients: a cohort study from Rio de
Janeiro, Brazil
Cardoso S, Luz P, Velasque L, et al
BMC Infect Dis. 2014 Dec
19;14(1):699.
Paper
FULL-TEXT ARTICLE
A Novel Acute Retroviral Syndrome Severity Score Predicts
the Key Surrogate Markers for HIV-1 Disease Progression.
Braun DL, Kouyos R, Oberle C, et al
PLoS One.
2014 Dec 9;9(12):e114111.
Paper
Preserving HIV-specific T cell responses:
does timing of antiretroviral therapy help?
Macatangay BJ, Rinaldo CR.
Curr Opin HIV AIDS.
2014 Nov 11
Abstract
Influence of the Timing of Antiretroviral Therapy on the
Potential for Normalization of Immune Status in Human Immunodeficiency Virus
1-Infected Individuals.
Okulicz JF, Le TD, Agan BK, et al
JAMA Intern Med. 2014 Nov 24
Abstract
The importance of viral blips and duration of therapy
initiated in primary infection in maintaining viral control after stopping
cART.
Fidler S, Olson A, Fox J, Phillips A, et al
J Int AIDS Soc. 2014 Nov
2;17(4(Suppl 3)):19820
Abstract
FULL-TEXT ARTICLE
Use of third line antiretroviral therapy in Latin America.
Cesar C, Shepherd BE, Jenkins CA,
PLoS
One. 2014 Sep
15;9(9):e106887.
Paper
FULL-TEXT
ARTICLE
Maximizing the benefits of antiretroviral
therapy for key affected populations.
Grubb IR, Beckham SW, Kazatchkine M, et al
J Int AIDS Soc.
2014 Jul 18;17(1):19320
Paper
Assessment of Second-Line Antiretroviral Regimens for HIV
Therapy in Africa.
Paton NI, Kityo C, Hoppe A, et al
N Engl J Med. 2014 Jul 17;371(3):234-47
Abstract
FULL-TEXT ARTICLE
The Clinical Impact of Continuing to Prescribe Antiretroviral Therapy in
Patients with Advanced AIDS Who Manifest No Virologic or Immunologic
Benefit.
Wohl DA, Kendall MA, Feinberg J, Alston-Smith B, et al
PLoS One. 2013 Nov 15;8(11):e78676.
Paper
Legal, ethical, and economic implications of breaking down
once-daily fixed-dose antiretroviral combinations into their single
components for cost reduction.
Ramiro MA, Llibre JM.
Enferm Infecc Microbiol Clin. 2013 Oct 16.
Abstract
Beyond first-line HIV treatment regimens: the current state
of antiretroviral regimens, viral load monitoring, and resistance testing in
resource-limited settings.
Kumarasamy N, Krishnan S.
Curr Opin HIV AIDS. 2013 Oct
4.
Abstract
Treatment optimization: an outline for future success.
Flexner C, Plumley B, Brown Ripin DH.
Curr Opin HIV AIDS.
2013 Oct 4..
Abstract
Effective treatment of a highly active antiretroviral regimen
through jejunostomy.
Florit-Sureda M, Giner-Soriano M, et al
J Chemother.
2013 Sep 27..
Abstract
Immune activation and HIV persistence: implications for curative
approaches to HIV infection.
Klatt NR, Chomont N, Douek DC, Deeks SG.|
Immunol Rev.
2013 Jul;254(1):326-42
Abstract
FULL-TEXT PDF ARTICLE
Management of HIV infection after triple class failure.
Cossarini F, Spagnuolo V, Gianotti N, et al
New Microbiol.
2013 Jan;36(1):23-39.
Paper |
Individualization
of antiretroviral therapy.
Pavlos R, Phillips EJ
Pharmgenomics Pers Med.
2012;5:1-17. .
Abstract |
No advantage of quadruple or triple-class
antiretroviral therapy as initial treatment in patients
with very
high viraemia.
Grijsen ML, Holman R, Gras L, et al
Antivir Ther.
2012 Aug 20..
Abstract
Neurocognitive Impact of Antiretroviral Treatment: Thinking
Long-Term.
McPhail ME, Robertson KR.
Curr HIV/AIDS Rep.
2011 Aug 12.
Abstract
Protective role of antiretroviral treatment in the
impairment of renal function in a
cohort of human immunodeficiency virus patients.
Mérida L, De la Torre J, Olalla J,
et al
Med Clin (Barc).
2011 Mar 10.
Abstract
High Dose Atorvastatin Decreases Cellular Markers of Immune Activation
without Affecting
HIV-1 RNA Levels: Results of a Double-Blind Randomized Placebo
Controlled Clinical Trial.
Ganesan A, Crum-Cianflone N, Higgins J, et al
J Infect Dis. 2011
Feb 15
Abstract
The impact of HIV drug resistance testing on
changes to treatment.
Bansi L, Smith C, Phillips A,
et al
AIDS.
2011 Feb
Abstract
FULL-TEXT PDF
ARTICLE
Antiretroviral Therapy Optimisation without Genotype
Resistance Testing: A Perspective on Treatment History
Based Models.
Prosperi MC, Rosen-Zvi M, Altmann A, et al
PLoS One.
2010 Oct 29;5(10):e13753
Paper |
Role of fixed-dose combinations of antiretrovirals in HIV-1
therapy.
Llibre JM, Antela A, Arribas JR, et al|
Enferm Infecc Microbiol Clin.
2010 Sep 29
Abstract |
The prognosis of patients with dissociated
virological and immunological responses
to HAART.
Jevtović D, Salemović D, Ranin J, et al
Biomed Pharmacother.
2010 Sep 20.
Abstract |
Optimal antiretroviral therapy: HIV-1 treatment strategies to
avoid and overcome
drug resistance.
Grant PM, Zolopa AR.
Curr
Opin Investig Drugs.
2010 Aug;11(8):901-10
Abstract |
Doctor-patient concordance during HIV treatment
switching decision-making.
Clucas C, Harding R, Lampe F,
et al
HIV Med.
2010 Jun 17.
Abstract |
Impact of antiretroviral treatment on (13)C-methionine metabolism
as a marker of
hepatic mitochondrial function: a longitudinal study.
Banasch M, Frank J, Serova K, et al
HIV Med. 2010 May
23.
Abstract |
Transient Lowering of the Viral Set Point After Temporary
Antiretroviral
Therapy of Primary HIV Type 1 Infection.
Steingrover R, Garcia EF, van Valkengoed IG,
et al
AIDS Res Hum Retroviruses.
2010 Apr 8
Abstract |
Predicting the magnitude of short-term CD4+ T-cell recovery in HIV-infected
patients
during first-line highly active antiretroviral therapy.
Castagna A, Galli L, Torti C, et al
Antivir Ther.
2010;15(2):165-75.
Abstract |
Therapy for persistent HIV.
Keedy KS, Margolis DM.
Trends Pharmacol Sci.
2010 Mar 4
Abstract |
Does Choice of Combination Antiretroviral Therapy (cART) Alter Changes in
Cerebral Function Testing after 48 Weeks in Treatment-Naive, HIV-1-Infected
Individuals Commencing cART? A Randomized, Controlled Study.
Winston A, Duncombe C, Li PC, et al
Clin Infect Dis. 2010 Feb 10.
Abstract |
Better than nothing: keeping pts on failing regimen has benefits.
Winslow DL.
AIDS Alert.
2009 Apr;24(4):44-5.
Abstract |
A WEEK-IN-REVIEW FEATURED REPORT
Importance of Dose Timing to Achieving Undetectable
Viral Loads.
Gill CJ, Sabin LL, Hamer DH, et al
AIDS Behav.
2009 Apr 8.
Abstract
|
Antiretroviral treatment strategies and immune reconstitution in
treatment-naïve HIV-infected
patients with advanced disease.
Soria A, Lazzarin A.
J Acquir Immune Defic Syndr. 2007
Sep;46 Suppl 1:S19-30.
Abstract
|
|
Conference Reports, Abstracts, and
Posters
|
| |
Therapeutic options in heavily pretreated HIV-1 patients based on the
genotypic resistance patterns
D Paraskevis, E Magiorkinis, G Magiorkinis, et al
(Ninth International Congress on Drug Therapy in HIV Infection)
Abstract
|
|
Journal Papers, Abstracts, and Commentaries
|
| |
Lower Pill Burden and Once-daily Dosing Antiretroviral Treatment
Regimens for HIV Infection: A Meta-Analysis of Randomized Controlled Trials.
Nachega JB, Parienti JJ, Uthman OA, et al
Clin Infect Dis. 2014 Jan
22.
Abstract
A survey of patients’ willingness to switch from a single-tablet
regimen to 2 pills once a day as a cost-saving strategy.
Tan J, Sonecha S, Mandalia S, Nelson M.
J Int AIDS Soc. 2012 Nov 11;15(6):18388
Abstract
Once-daily single-tablet regimens: a long and winding road to
excellence in antiretroviral treatment.
Llibre JM, Clotet B.
AIDS Rev. 2012 Jul;14(3):168-78.
Abstract
One-pill once-a-day HAART: a simplification strategy that improves adherence
and quality of life of HIV-infected subjects.
Airoldi M, Zaccarelli M, Bisi L, et al
Patient Prefer Adherence. 2010 May 13;4:115-25.
Abstract |
Conference Reports, Abstracts, and
Posters
| |
Once-daily regimens were associated
with a higher rate of self-chosen discontinuations
Murri R, Cingolani A,
De Luca A, Di Giambenedetto S,, et al
(Ninth International Congress on Drug Therapy in HIV Infection)
Abstract |
POSTER
Once-Daily Versus Twice-Daily Regimens: Which is Best for HIV Infected
Patients?
B. VrijensL.Comté, E. Tousset J. Urquhart
(7th International Workshop on Clinical Pharmacology of HIV
Therapy)
PDF Poster |
|
|
Journal Papers, Abstracts, and Commentaries
|
Journal Papers, Abstracts, and Commentaries
| |
Monotherapy with boosted PIs as an ART simplification
strategy in clinical practice
Santos JR, Llibre JM, Berrio-Galan D, et al
J Antimicrob Chemother. 2014 Dec
18.
Abstract
Nuke-sparing regimens as a main simplification strategy
and high level of toxicity resolution after antiretroviral switch: the
SWITCHART Study.
Carrero-Gras A, Antela A, Muñoz-Rodríguez J, Díaz-Menéndez M, et
al
J Int AIDS Soc.
2014 Nov 2;17(4(Suppl 3)):19819.
Abstract
Simplification of antiretroviral therapy: a necessary
step in the public health response to HIV/AIDS in resource-limited
settings.
Vitoria M, Ford N, Doherty M, Flexner C.
Antivir Ther. 2014;19(Suppl 3):31-37
Abstract
Optimization and simplification of antiretroviral therapy
for adults and children.
Ford N, Flexner
C, Vella S, et al
Curr Opin HIV AIDS. 2013 Oct 4
Abstract
Simplification of antiretroviral therapy: a good choice for our patients and
the sustainability of our health care system.
González Rivas L, Sánchez Gómez E,
et
al
Farm Hosp. 2011 Oct 19.
Abstract
Treatment simplification in HIV-infected adults as a strategy to
prevent toxicity,
improve adherence, quality of life and decrease healthcare costs.
Nachega JB, Mugavero MJ, Zeier M,
et al
Patient Prefer Adherence.
2011;5:357-6
Abstract
One-pill once-a-day HAART: a simplification strategy that improves adherence
and quality of life of HIV-infected subjects.
Airoldi M, Zaccarelli M, Bisi L, et al
Patient Prefer Adherence.
2010 May 13;4:115-25.
Abstract |
Simplification strategies to reduce antiretroviral drug exposure:
progress and prospects.
McKinnon JE, Mellors JW, Swindells S/
Antivir Ther.
2009;14(1):1-12.
Abstract
|
Benefits and concerns of simplification strategies in HIV-infected patients.
Negred E, Bonjoch A, Clotet B.
J Antimicrob Chemother. 2006 Jun 27;
Abstract
|
|
Conference Reports, Abstracts, and
Posters
| |
Improved treatment adherence associated with treatment
simplification
Baker D, Vale R, Doong N, et al
(4th IAS Conference)
Abstract
|
Effect of Antiretroviral Simplified Regimens on Cellular HIV-DNA Levels-
G. D’ETTORRE M. CARNEVALINI, C. ANDREONI, et al
(45 ICAAC)
Abstracts |
|
|
HAART
Main Page